Anti-GATA3 gene therapy (sterna biologicals)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAnti-GATA3 gene therapy (sterna biologicals)
Drug Alias NameHuman GATA-3-specific DNAzyme solutionAnti-GATA-3 gene therapySB-011SB-010hgd40 +[6] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionTrans-acting T-cell-specific transcription factor GATA-3 inhibitorsGene transference
TargetsTrans-acting T-cell-specific transcription factor GATA-3
Therapy Area/IndicationsDermatitis, AtopicAsthmaColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MarburgSterna Biologicals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSterna Biologicals Gmbh & Co Kg
Active IndicationsN/A
Inactive IndicationsDermatitis, AtopicAsthmaColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A